Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrawound Vancomycin for Inguinal Lymph Node Dissection
NCT05625373Phase 3Recruiting
- Sponsor
- Women & Infants Hospital
- Start
- Oct 2022
- Primary completion
- Apr 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by Women & Infants Hospital. Primary endpoint: Composite rate of postoperative complications at 30 days. Started Oct 2022; status: recruiting.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05625373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625373.